Carvykti denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for carvykti are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Carvykti for Medical Necessity

Aetna's clinical policy for Carvykti (ciltacabtagene autoleucel) includes specific medical necessity criteria that a patient's chart must satisfy before the therapy will be authorized. These criteria are derived from the FDA-approved prescribing information and Aetna's own clinical policy bulletin, and typically address the number and type of prior lines of therapy, disease status at the time of the request, and performance status. A medical necessity denial means Aetna's reviewer concluded that the submitted documentation did not demonstrate that all criteria were met — not necessarily that the patient does not meet them.

## Why This Denial Is Appealable

Medical necessity denials are often reversed when the appeal provides a complete, organized record that maps each policy criterion to a specific chart finding. The most common reason these denials are upheld on appeal is incomplete documentation — a missing response assessment, an incompletely documented prior-therapy line, or an absent performance status notation — rather than a genuine failure to meet clinical criteria. Your oncologist's involvement in building the appeal is essential.

## Federal Appeal Framework

• Internal appeal: Under ERISA §503 or applicable state law, you have the right to a full-and-fair internal review. Submit within the deadline on your denial letter, which is typically 60 to 180 days.
• External review: Under ACA §2719, after a final internal denial you may request independent external review by an accredited IRO, generally within four months.
• Expedited review: Simultaneously request expedited external review — decisions are rendered within 72 hours. Given the serious, life-threatening nature of relapsed/refractory multiple myeloma, expedited review is almost always appropriate.

## Documentation to Gather

• Complete prior-therapy history: A table listing every prior line of therapy by name (as recorded in the chart), start and end dates, best response, reason for discontinuation, and any documented toxicity. Aetna's policy specifies a minimum number of prior lines; verify against the current policy bulletin and confirm each line is independently documented.
• Current disease-status records: Bone marrow biopsy with pathology report, serum protein electrophoresis or free light chain labs, and most recent imaging, all dated close to the authorization request.
• Performance status documentation: An explicit ECOG or Karnofsky performance status notation in the most recent clinic note, with the date. This is frequently the missing element.
• Leukapheresis and manufacturing feasibility: Documentation from the treating center confirming the patient is a candidate for CAR-T infusion.
• Oncologist medical-necessity letter: Should walk through each Aetna criterion explicitly, cite the supporting chart document, and confirm the patient meets the FDA-approved indication as stated in the prescribing information.

## Criteria-Mapping Structure

Obtain Aetna's current clinical policy bulletin for Carvykti. Create a table with four columns: (1) Aetna Criterion, (2) FDA Label Requirement (reference the label rather than quoting numbers), (3) Patient's Chart Finding, (4) Supporting Document and Date. Submit this table as the first page of your appeal letter. This format allows the reviewer to complete their assessment without having to search through a large exhibit packet and is the single most effective structural change you can make to a medical-necessity appeal for a CAR-T therapy.